A controversial marketing campaign touting a cigarette-like product as less likely than conventional cigarettes to cause cancer and other smoking-related illnesses is drawing fire from public health officials, scientists, and antismoking advocates. The new marketing effort comes only 4 weeks after the US Supreme Court ruled that the Food and Drug Administration (FDA) lacks the authority to regulate tobacco products.
At R. J. Reynolds Tobacco Holdings (RJR) Inc's annual shareholders meeting, CEO Andrew J. Schindler announced that RJR was marketing a cigarette called Eclipse with the claim that the product may present smokers with "less risk of cancer and certain other diseases, such as chronic bronchitis and possibly emphysema."As part of the new marketing campaign, RJR is using newspaper and magazine advertising along with direct marketing, aimed primarily at consumers in the Dallas–Fort Worth area. Until now, the product has been available only in test markets in Chattanooga, Tenn; Lincoln, Neb; and parts of Atlanta.
Magazines, primarily in the Dallas–Fort Worth area, will feature this advertisement for Eclipse, which claims the reduced-smoke product may present less risk of cancer and other smoking-related illnesses than conventional cigarettes. Critics charge that no independent studies exist to support such claims. (Credit: PRN)
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 5
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
The Rational Clinical Examination: Evidence-Based Clinical Diagnosis
All results at
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.